Miriam Rios
About Miriam Rios
Miriam Rios is the Director of Supplier & Quality Systems Management and Compliance at AlloVir, with over 30 years of experience in the pharmaceutical industry. She specializes in quality assurance, regulatory compliance, and the enhancement of quality systems.
Current Role at AlloVir
Miriam Rios serves as the Director of Supplier & Quality Systems Management and Compliance at AlloVir. She has held this position since 2021, contributing to the company's focus on quality assurance and regulatory compliance. Her role involves overseeing supplier quality systems and ensuring adherence to compliance standards within the organization. Rios's extensive experience in the pharmaceutical industry supports her effectiveness in this position.
Previous Experience in the Pharmaceutical Industry
Miriam Rios has over 30 years of experience in the pharmaceutical industry, with a focus on quality assurance and regulatory compliance. She has held various positions at notable companies, including Vertex Pharmaceuticals, where she worked as Associate Director of Quality Standards, Training & Improvements from 2020 to 2021. At Genzyme, she served as Quality Systems Manager from 2011 to 2018, managing change control and consent decree processes. Her career also includes roles at Brammer Bio, GlaxoSmithKline, Aventis Pharmaceutical, IVAX Pharmaceuticals, and Pharmacia.
Education and Qualifications
Miriam Rios earned her Bachelor's Degree from Tufts University. Her educational background, combined with her extensive professional experience, provides her with a strong foundation in quality systems and regulatory compliance within the pharmaceutical sector.
Expertise in Quality Systems and Compliance
Rios specializes in compliance enhancement for quality systems and the development of global quality policies and procedures. She possesses strong knowledge of Good Manufacturing Practices (GMP) and regulations applicable in the US, EU, and Rest of the World. Her expertise includes designing, implementing, and continuously improving quality management systems, as well as consent decree remediation and verification of pharmaceutical quality systems.